Skip to main content

Table 1 Patient demographics and disease characteristics at baseline

From: Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies

 

Current smoker

Ex-smoker

GLY (n = 251)

Placebo (n = 245)

Total (N = 496)

GLY (n = 186)

Placebo (n = 185)

Total (N = 371)

Age, years, median (range)

61.0 (44, 83)

60.0 (41, 84)

60.0 (41, 84)

68.0 (43, 86)

67.0 (48, 87)

67.0 (43, 87)

Male, n (%)

142 (56.6)

151 (61.6)

293 (59.1)

109 (58.6)

102 (55.1)

211 (56.9)

Race, n (%)

 Caucasian

223 (88.8)

207 (84.5)

430 (86.7)

172 (92.5)

166 (89.7)

338 (91.1)

 Black

22 (8.8)

35 (14.3)

57 (11.5)

8 (4.3)

11 (5.9)

19 (5.1)

 Asian

1 (0.4)

0

1 (0.2)

2 (1.1)

3 (1.6)

5 (1.3)

 Native American

2 (0.8)

2 (0.8)

4 (0.8)

0

2 (1.1)

2 (0.5)

 Other

3 (1.2)

1 (0.4)

4 (0.8)

4 (2.2)

3 (1.6)

7 (1.9)

Duration of COPD, years, median (range)

4.7 (0.0, 19.0)

4.9 (0.0, 29.9)

4.8 (0.0, 29.9)

6.1 (0.0, 28.6)

6.0 (0.0, 32.6)

6.0 (0.0, 32.6)

Airflow obstruction (GOLD 2011 [16]), n (%)

 Mild (GOLD 1)

0

1 (0.4)

1 (0.2)

0

0

0

 Moderate (GOLD 2)

166 (66.1)

165 (67.3)

331 (66.7)

111 (59.7)

102 (55.1)

213 (57.4)

 Severe (GOLD 3)

83 (33.1)

75 (30.6)

158 (31.9)

72 (38.7)

81 (43.8)

153 (41.2)

 Missing

2 (0.8)

4 (1.6)

6 (1.2)

3 (1.6)

2 (1.1)

5 (1.3)

Combined assessment of COPD (GOLD 2011 [16]), n (%)

 Group A

1 (0.4)

0

1 (0.2)

0

1 (0.5)

1 (0.3)

 Group B

161 (64.1)

157 (64.1)

318 (64.1)

108 (58.1)

94 (50.8)

202 (54.4)

 Group C

0

0

0

0

0

0

 Group D

87 (34.7)

84 (34.3)

171 (34.5)

75 (40.3)

88 (47.6)

163 (43.9)

 Missing

2 (0.8)

4 (1.6)

6 (1.2)

3 (1.6)

2 (1.1)

5 (1.3)

Estimated number of pack-years, median (range)

46.0 (10.0, 146.5)

48.0 (11.0, 184.0)

47.0 (10.0, 184.0)

46.0 (12.5, 240.0)

49.0 (10.0, 156.0)

47.0 (10.0, 240.0)

ICS use at baseline, n (%)

56 (22.3)

66 (26.9)

122 (24.6)

65 (34.9)

65 (35.1)

130 (35.0)

Pre-bronchodilator FEV1, mean (SD)

 Volume, L

1.3 (0.5)

1.4 (0.5)

1.4 (0.5)

1.3 (0.4)

1.2 (0.5)

1.2 (0.5)

 % predicted

46.7 (12.8)

47.3 (12.9)

47.0 (12.8)

45.9 (12.8)

44.9 (13.5)

45.4 (13.2)

Post-bronchodilator FEV1, mean (SD)

 Volume, L

1.6 (0.5)

1.6 (0.5)

1.6 (0.5)

1.5 (0.5)

1.4 (0.5)

1.4 (0.5)

 % predicted

55.5 (12.9)

56.3 (12.7)

55.9 (12.8)

53.2 (13.5)

52.7 (13.6)

53.0 (13.5)

FVC, L, mean (SD)

 Pre-bronchodilator

2.6 (0.9)

2.7 (0.9)

2.7 (0.9)

2.6 (0.8)

2.5 (0.8)

2.6 (0.8)

 Post-bronchodilator

3.1 (0.9)

3.1 (0.9)

3.1 (0.9)

2.9 (0.9)

2.9 (0.9)

2.9 (0.9)

FEV1/FVC, %

 Pre-bronchodilator

50.9 (10.2)

50.8 (9.9)

50.8 (10.0)

48.9 (11.0)

47.1 (10.7)

48.0 (10.8)

 Post-bronchodilator

52.2 (10.2)

52.3 (9.8)

52.2 (10.0)

50.4 (11.1)

49.1 (10.8)

49.8 (10.9)

  1. COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, GLY glycopyrrolate, ICS inhaled corticosteroid, SD standard deviation